Trial Profile
A Randomized, Open-label, Japan-Korea-Taiwan Collaborative Phase 3 Study to Compare the Efficacy of Nimotuzumab and Irinotecan Combination Therapy Versus Irinotecan Monotherapy as Second Line Treatment in Subjects With Advanced or Recurrent Gastric and Gastroesophageal Junction Cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Irinotecan
- Indications Gastric cancer; Gastrointestinal cancer
- Focus Registrational; Therapeutic Use
- Acronyms ENRICH
- Sponsors Kuhnil Pharmaceutical Company
- 23 Mar 2018 Status changed from active, no longer recruiting to discontinued.
- 26 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Jul 2016 Planned primary completion date changed from 1 Dec 2014 to 1 Jan 2018.